---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-030137"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:03:51.445247+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen Q2 net loss $0.10/share; cash at $70.6M; INDs cleared for two gene therapies

## Summary
- Cash, cash equivalents & investments $70.6M at June 30, 2023, down from $90.9M at Dec 31, 2022.
- Net loss per share $0.10 for Q2 2023 vs $0.09 a year ago; includes $4.4M non-cash impairment on COVAXIN supply asset.
- Operating expenses $23.7M (R&D $14.2M, G&A $9.6M); R&D includes $4.4M impairment and disposal loss.
- FDA cleared INDs for OCU410 (geographic atrophy) and OCU410ST (Stargardt disease); Phase 1/2 trials planned by year-end.
- OCU400 Phase 3 trial expected to begin late 2023/early 2024; updated Phase 1/2 results due this quarter.

## SEC filing metadata
- accession: 0001628280-23-030137
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/0001628280-23-030137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/ocgn-20230821.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-030137
- JSON: https://secwatch.observer/filing/0001628280-23-030137.json
- Plain text: https://secwatch.observer/filing/0001628280-23-030137.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported second quarter ended June 30, 2023 results: net income $0.10 net loss per common share, EPS $0.10 net loss per common share.
  - Period: second quarter ended June 30, 2023
  - Net income: $0.10 net loss per common share
  - EPS: $0.10 net loss per common share
  - Result: reported results
  source text: Ocugen reported a $0.10 net loss per common share for the three months ended June 30, 2023 compared to a $0.09 net loss per common share for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/0001628280-23-030137-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.